Kornimate/medical-research-clean huggingface dataset:
efficacy and safety study: repetitive transcranial magnetic stimulation (rtms) for treating movement disorders in patients with intracranial hemorrhage (ich).

Conditions: Intracerebral Hemorrhage

Summary: this pilot study aims to assess the effectiveness and safety of rtms in the treatment of movement disorders in patients with ich.

while the fatality rate of intracerebral hemorrhage (ich) has decreased, many patients continue to experience persistent limb movement dysfunction. motor dysfunction in ich is commonly attributed to basal ganglia hemorrhage, as the basal ganglia play a central role in the extrapyramidal motor system. therefore, promoting the remodeling of the extrapyramidal motor system holds great significance for effectively treating ich patients with movement disorders. repetitive transcranial magnetic stimulation (rtms) is a safe and non-invasive neuromodulation technique that can modulate neuronal activity, influence neuronal synaptic plasticity, and enhance brain function. currently, rtms has shown promise in improving motor function among patients with stroke and those who have undergone brain tumor surgery, which provides valuable insights for its potential application in patients with motor dysfunction following ich surgery. this pilot study aims to evaluate the efficacy and safety of rtms in the treatment of ich patients with movement disorders. the participants will be randomly assigned to either a real rtms treatment group or a sham group. the study will assess and compare various clinical outcomes, including the fma (fugl-meyer assessment), nihss (national institutes of health stroke scale), and bi (barthel index) scores, over a period of 6 months.

Eligibility criteria:
inclusion criteria: 1. participants between the ages of 45 and 65 years old. 2. more than 1 month and less than 3 months after ich 3. with severe and moderately severe motor functional impairment, indicated by a functional motor assessment (fma) score ranging from 0 to 55. 4. unilateral basal ganglia hemorrhage with a hematoma volume of 30-60ml, measured using the abc2 method based on preoperative ct scans. 5. participants should have a stable level of consciousness, with a score of 0 to 1 on the level of consciousness, level of consciousness questions, and level of consciousness instructions of the national institutes of health stroke scale (nihss), along with stable vital signs. 6. underwent surgical treatment for ich within 2 weeks after the event, utilizing either craniotomy or endoscopic hematoma evacuation, with an evacuation rate of at least 80%. 7. signed the informed consent. exclusion criteria: 1. with a history of epilepsy. 2. with movement disorders resulting from causes other than basal ganglia hemorrhage. 3. with severe general impairment or coexisting medical conditions. 4. with emotional issues or cognitive impairments, as indicated by a mini-mental state examination (mmse) score below 21. 5. with any contraindications to transcranial magnetic stimulation (tms), such as having metal implants in the brain or using a pacemaker.

Keywords: intracerebral hemorrhage movement disorders repetitive transcranial magnetic stimulation
the effect of hypnosis on periodontal treatment

Conditions: Peridontal Disease; Dental Anxiety

Summary: treatment of periodontal diseases relies on the mechanical removal of microbial dental plaque, calculus, and necrotic cementum from root surfaces in both supra- and subgingival areas to control inflammation in periodontal tissues. as in all dental treatments, dental phobia and dental anxiety are common challenges in initial periodontal therapy. hypnosis is among the traditional non-pharmacological behavior management techniques used to manage stress and improve pain tolerance. it is known that hypnosis is effective in anxiety control in dentistry. the use of salivary levels of inflammatory mediators released during the disease is a valid method for assessing the progression of periodontal disease and healing after treatment. in this study, the effect of hypnosis on healing in patients undergoing phase i periodontal therapy will be evaluated by comparing the mean differences in cytokine levels between case and control groups


Eligibility criteria:
inclusion criteria: being between the ages of 20-65 not having any systemic disease having chronic periodontal disease having the ability to understand the study and answer questions exclusion criteria: having any systemic disease being under 20 or over 65 not having any periodontal disease

Keywords: periodontitis, hypnosis, dental anxiety
impact of surgical injury on haemostatic tests in patients undergoing total hip replacement with subgroup analysis of patients with neoplasm

Conditions: Total Hip Replacement; Thromboelastometry; Bone Neoplasm of Hip

Summary: total hip replacement (thr) is associated with extensive tissue injury and considerable blood loss that can be complicated by hyperfibrinolysis with an increased need for blood transfusion. thr in patients with cancer involving the hip joint, can reduce pain and improve or maintain the function and quality of life. however, these patients have an increased likelihood of haemostatic abnormalities, such as thrombosis or extensive blood loss. rotational thromboelastometry is a point-of-care viscoelastic assay that can provide a measure of coagulation disorders in the above settings, and this is still under review. the objective of this prospective cohort study is to quantitate the changes in clot formation dynamics following thr with a subgroup analysis of patients with cancer.


Eligibility criteria:
inclusion criteria: * adult patients undergoing primary elective total hip replacement exclusion criteria: * patients unable to consent to trial * active deep and superficial vein thrombosis * coagulopathy in initial coagulation screen tests * platelet count below 100 thousand * patients on antithrombotic medications (except prophylactic low molecular weight heparins and acetylsalicylic acid up to 75 mg per day) * preoperative haemoglobin \< 10 g/dl * female patients who are pregnant or nursing
clinical efficacy trial of mexiletine for myotonic dystrophy type 1

Conditions: Myotonic Dystrophy

Summary: the purpose of this study is to investigate the effects of mexiletine treatment for 6 months on ambulation, myotonia, muscle function and strength, pain, gastrointestinal functioning, cardiac conduction, and quality of life in myotonic dystrophy type 1 (dm1).

this study will provide data on the long term (6 months) safety and efficacy of mexiletine in: * improving the distance participants are able to walk in six minutes; * reducing myotonia; * improving muscle strength; * increasing lean muscle mass; * decreasing musculoskeletal pain; * improving gastrointestinal function and swallowing); * improving functional abilities; * decreasing cardiac arrhythmias; and * improving disease-specific health related quality-of-life.

Eligibility criteria:
inclusion criteria: * a diagnosis of dm1, confirmed by dm1 genetic mutation * ability to walk 30 feet (assistance with cane and/or leg bracing permitted) * presence of grip myotonia exclusion criteria: * congenital dm1 * treatment with mexiletine within past 8 weeks * second or third degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia * receiving another antimyotonia drug * liver or kidney disease requiring ongoing treatment * has a seizure disorder * is pregnant or lactating * had severe depression within 3 months or a history of suicide ideation * has any one of the following medical conditions: uncontrolled diabetes mellitus, congestive heart failure, symptomatic cardiomyopathy, symptomatic coronary artery disease, cancer (other than skin cancer) less than five years previously, multiple sclerosis, or other serious medical illness. * drug or alcohol abuse within 3 months * coexistence of another neuromuscular disease * is unable to give informed consent * severe arthritis or other medical condition (besides dm1) that would significantly impact ambulation

Keywords: myotonic dystrophy myotonic dystrophy type 1 (dm1) muscular dystrophy mexiletine
effects of fatmax exercise and hiit on fat loss in overweight young women

Conditions: Overweight

Summary: this study investigated the effects of two exercise modalities: high-intensity interval training (hiit) and maximal fat oxidation (fatmax) exercise on fat loss in overweight young women. participants were randomly assigned to either the hiit or fatmax group, underwent an 8-week supervised exercise intervention.

this study aims to compare the effects of hiit and fatmax exercise on fat loss in overweight young women. participants were recruited and randomly assigned to either the hiit group or the fatmax group. the intervention lasted for 8 weeks, during which participants maintained their usual diet. both body morphology and body composition were assessed before and after the intervention. in order to recommend exercise strategy for overweight young women reduce fat and improve their health.

Eligibility criteria:
inclusion criteria: * female, aged between 18 and 30 years. * overweight, bmi greater than 24.0 kg·m-2. * participants lack of exercise habits. * participants without significant fluctuation in weight. exclusion criteria: * participants took drugs affecting metabolism and hormones during the experimental period. * participants had a history of oral weight loss pills and contraceptive pills. * participants had a history of smoking, alcohol consumption, or daily consumption of caffeine-containing beverages. * participants had cardiovascular or basal metabolic disorders, such as hypertension, coronary heart disease, or diabetes mellitus. * participants had other acute or chronic injuries related to exercise.

Keywords: high-intensity interval training maximal fat oxidation overweight fat loss female
lactobacillus plantarum is 10560 supplementation in women with functional constipation

Conditions: Constipation - Functional

Summary: in this study, the investigators measured the scfa (butyrate, acetate and propionate) as a biomarker improvement symptom and quality of life women with functional constipation after supplementation of commensal bacterial fermented milk lactobacillus plantarum (isolated from indigenous probiotics from dadih, west sumatra) for 21 days


Eligibility criteria:
inclusion criteria: * being declared healthy based on initial examination and the structured interview questionnaire (siq) * having the symptoms and signs of functional constipation refer to rome iv * able to communicate well * able to consume 1 bottle of fermented milk each day for three weeks * not using antibiotic no later than one week before supplementation exclusion criteria: * diagnosed with functional bowel disorder * using anesthesia at least 4 weeks before treatment * having a serious pathological disorder (carcinoma) * during healing phase of acute gastrointestinal disorders at least 4 weeks before treatment * having severe heart disease * taking chronic medications such as antidepressants or analgesics

Keywords: scfa probiotic lactobacillus plantarum functional constipation
a prospective observational case series of a four-ring-haptic acrylic one-piece iol

Conditions: Cataract

Summary: to describe biocompatibility, postoperative results and complications after implantation of the corneal quatrix evolutive (corneal, croma, austria) intraocular lens, a hydrophilic acrylic intraocular lens (iol) with 4-haptic design and 360° sharp optic edge.

in this prospective case series the corneal quatrix evolutive iol was implanted in 14 eyes of nine patients with senile cortico-nuclear cataract. a standardized surgical technique and post-operative regimen were applied. six months postoperatively best corrected visual acuity (bcva), refraction and complications (especially) posterior capsule opacification (pco) were analysed.

Eligibility criteria:
inclusion criteria: patients with senile cortico-nuclear cataracts without previous intraocular surgery exclusion criteria: * dilated pupil size of \< 6 mm * long-term anti-inflammatory treatment * previous history of intraocular surgery * previous history of corneal endothelial damage * previous history of ocular trauma * traumatic cataract * history of uveitis * diabetic retinopathy * advanced macular degeneration

Keywords: best-corrected visual acuity posterior capsule opacification quatrix® aspheric evolutive pre-loaded
comparison between bupivacaine and bupivacaine with dexmedetomidine in caudal block for post operative pain control

Conditions: Post Operative Pain

Summary: the aim of this study is to compare the duration of analgesia, sedation, and intra and postoperative hemodynamics. this drug is recently available in pakistan. to the best of our knowledge, no published data is available in this respect in pakistan, so this study would in turn help to fill the gap in knowledge in low-resource settings/emerging economy.

postoperative pain is an annoying subjective sensation for both children and their parents. almost 80% of the patients undergoing surgery experience postoperative pain, and 80% of them reported moderate to severe pain intensity. management of postoperative pain has become a major concern in pediatrics. results of many studies in different countries show that postoperative pain in children is inadequate. lee et al showed that one of the main reasons for inadequate treatment of postoperative pain in children is difficulties with pain assessment and concerns related to the side effects of opioid analgesics. the regional anesthetic technique significantly decreases postoperative pain and systemic analgesic requirements. caudal block, usually combined with general anesthetic technique is one of the most popular, reliable, and safe anesthesia techniques for abdominal and lower limb surgeries in children but the main disadvantage of caudal analgesia is the short duration of action after a single injection. bupivacaine is a long-acting, reliable local anesthetic agent that is used as a caudal analgesic, but different auxiliary agents need to be co-administered to improve its analgesic efficiency. various additives used in the past to increase the pain-free period postoperatively and to decrease the analgesic requirement such as midazolam neostigmine, ketamine, clonidine, and dexmedetomidine. dexmedetomidine is a potent and highly selective alpha 2 adrenergic agonists that has been described as safe and effective in many anesthetic applications and analgesic techniques. in contrast to other agents, it has sympatholytic, analgesic, and sedative effects, and is randomly free from side effects except for manageable hypotension and bradycardia.

Eligibility criteria:
inclusion criteria: * asa 1 \& 2 * elective per-urethral cystolithotripsy exclusion criteria: * history of developmental delay or mental retardation * known or suspected coagulopathy * known allergy to any of the study drugs * any signs of infection at the site of the proposed caudal block * any caudal anatomical deformity
anemia correction and fibroblast growth factor 23 levels in chronic kidney disease , and renal transplant patient

Conditions: Anemia of Chronic Kidney Disease; Endothelial Dysfunction; Left Ventricular Hypertrophy; Fibroblast Growth Factor 23

Summary: the fibroblast growth factor-23-bone-kidney axis is part of newly discovered biological systems linking bone to other organ functions through a complex endocrine network that is integrated with the parathormone/vitamin d axis and which plays an equally important role in health and disease . most of the known physiological function of fibroblast growth factor 23 to regulate mineral metabolism can be accounted for by actions of this hormone on the kidney.in a recent experimental study, fibroblast growth factor-23 was shown to cause pathological hypertrophy in rat cardiomyocytes by "calcineurin-nuclear factor of activated t cells" and treatment with fibroblast growth factor -blockers reduced left ventricular hypertrophy in experimental models of chronic renal failure.the current hypothesis is that, in healthy individuals, iron deficiency stimulates increased production of fibroblast growth factor23. at the same time, iron is thought to be the cofactor of enzymes taking part in the degradation of intact fibroblast growth factor-23 and thought to have a role in the excretion of degraded fgf-23 parts .studies speculated that angiotensin converting enzyme inhibitors may exert their anti-proteinuria effects at least in part by reducing serum fibroblast growth factor-23 levels although it is difficult from the results of this study to understand which comes first and brings about the other; decrease in proteinuria or fibroblast growth factor-23. available evidence points to the deleterious effects of increased fibroblast growth factor-23 level in proteinuria, but the precise molecular mechanism still remains to be explored. an intricate and close association exists among parathormone, phosphorus, active vitamin d with fgf23, but the independent role of the latter on proteinuria is the least explored. elaborately conducted studies that control effects of confounding factors adequately are needed to demonstrate the independent pathogenic role of fgf23.

1. to study the effect of anemia correction and left ventricular hypertrophy in chronic kidney disease patients and renal transplant patients . 2. to study the relation of fibroblast growth factor and left ventricular hypertrophy in chronic kidney disease and renal transplant patients. 3. to study the relation between fibroblast growth factor 23 and early endothelial dysfunction in both chronic kidney disease and renal transplant patients.

Eligibility criteria:
inclusion criteria: all patients: 1. above 18 years old 2. diagnosed as ckd, and renal transplanted patients at assiut university hospital in the period 2017-2020 . exclusion criteria: 1. severely hypocalcaemic patients \< 7mg/dl. 2. severely hyperphosphatemic patients \>7 mg/dl . 3. uncontrolled hypertensive patients ( more than 3 antihypertensive drugs). 4. uncontrolled diabetic patients hba1c \>8 . 5. blood transfusion dependent
study of obeldesivir to treat children with respiratory syncytial virus (rsv) infection

Conditions: RSV Infection

Summary: the goal of this clinical study is to check if obeldesivir (odv; gs-5245) is safe and well-tolerated by children with respiratory syncytial virus (rsv) infection. it will also look at how well odv helps reduce the time it takes for children to feel better and for their rsv symptoms to improve. the primary objectives of this study are: a) to evaluate the safety and tolerability of odv in pediatric participants with rsv infection; b) to evaluate the efficacy of odv on time to alleviation of targeted rsv symptoms in pediatric participants with rsv infection.

pediatric participants will be enrolled as follows: * cohort 1: infants and children from 4 weeks postnatal age, weighing ≥ 1.5 kg to \< 40 kg * cohort 2: neonates, either born at term or preterm, weighing ≥ 1.5 kg to \< 6 kg

Eligibility criteria:
key inclusion criteria: * participants assigned male or female at birth, from birth to \< 5 years of age who meet one of the following criteria, where permitted according to local law and approved nationally and by relevant institutional review board or independent ethics committee: * cohort 1: infants and children from 4 weeks postnatal age, weighing ≥ 1.5 kg to \< 40 kg * cohort 2: neonates, either born at term or preterm, weighing ≥ 1.5 kg to \< 6 kg * rsv infection diagnosis ≤ 3 days prior to randomization. * negative test for influenza a/b, and sars-cov-2 infection ≤ 7 days prior to randomization. * onset of rsv signs or symptoms ≤ 3 days prior to randomization. * presence of at least 1 sign or symptom of rsv infection at screening and at randomization. key exclusion criteria: * currently requiring or expected to require hospitalization for rsv infection within 48 hours after randomization. * documented previous infection and/or hospitalization for rsv during the current respiratory virus season. * diagnosed with acute concurrent active systemic infections requiring treatment with systemic antiviral, antibacterial, antifungal, or antimycobacterial therapy, or with any documented respiratory viral infection (other than rsv), ≤ 7 days prior to randomization. * history of asthma or recurrent wheezing. * neuromuscular disease that affects swallowing. * cystic fibrosis. * participants who are immunocompromised. * alanine aminotransferase ≥ 5 × upper limit of normal (uln). * abnormal renal function. * concurrent or previous treatment with other agents with actual or possible direct antiviral activity against rsv, received within 28 days or within 5 half-lives, whichever is longer, prior to randomization. * received palivizumab within 100 days, or nirsevimab within 1 year, or other rsv specific monoclonal antibody within 5 half-lives of the antibody, prior to randomization. * participant whose mother received rsv vaccination during pregnancy and who is \< 1 year old prior to randomization. note: other protocol defined inclusion/exclusion criteria may apply.
early anatomy scan for evaluation of obese pregnant women (ease-o)

Conditions: Obesity

Summary: the purpose of this study is to assess the feasibility of ultrasound in the first trimester, assess the completion rate of ultrasounds for fetal anatomy in the first trimester compared to completion rates of ultrasounds for fetal anatomy in the second trimester and to assess the completion rate of the combination of one ultrasound in the first trimester and one in the second trimesters compared to the individual completion rates of both evaluations in obese pregnant women.


Eligibility criteria:
inclusion criteria: * bmi greater than or equal to 35 * presented for ultrasound before 14 weeks at the university of texas professional building, memorial city, bellaire, or lyndon-baines johnson clinics * primary language is english or spanish * consent to an extra transvaginal ultrasound if needed * singleton gestation * no previous anomalies known before consent * missed abortion (nonviable pregnancy) exclusion criteria: * elective abortion after recruitment * missed abortion after first trimester ultrasound * did not receive second trimester ultrasound

Keywords: pregnancy fetal ultrasound